Table 1. Short chain fatty acids (SCFA) in anorexia nervosa patients (AN) before (T1) and after (T2) weight gain compared to normal-weight participants (NW).
| A | SCFA [μmol/g] |
|||
|---|---|---|---|---|
| ANT1 | ANT2 | NW | Group differences | |
| Median [IQR] | Median [IQR] | Median [IQR] | ||
| Total SCFA | 39.5 [27.1–56.8] | 43.8 [26.8–68.6] | 43.5 [29.8–65.7] | n.s. |
| Acetate | 25.6 [18.5–35.8] | 29.3 [16.6–43.9] | 29.9 [20.5–41.5] | n.s. |
| Butyrate | 4.4 [2.5–6.8] | 6.1 [3.1–10.4] | 5.4 [3.4–11.8] | n.s. |
| Propionate | 5.7 [3.4–7.6] | 6.8 [4.3–10.2] | 6.7 [4.1–10.3] | n.s. |
| Valerate | 1.2 [0.9–1.5] | 1.1 [0.6–1.6] | 0.7 [0.4–1.2] | ANT1-NW***, ANT2-NW* |
| Total BCFA | 1.9 [1.5–2.3] | 1.7 [1.2–2.4] | 1.3 [0.8–2.1] | ANT1-NW*, ANT2-NW* |
| Iso-valerate | 0.9 [0.7–1.2] | 0.9 [0.6–1.4] | 0.7 [0.4–1.2] | n.s. |
| Iso-butyrate | 0.9 [0.7–1.2] | 0.9 [0.5–1.1] | 0.6 [0.3–0.9] | ANT1-NW*, ANT2-NW* |
| B | Relative proportion of specific SCFA in relation to total SCFA [%] | |||
| ANT1 | ANT2 | NW | ||
| Median [IQR] | Median [IQR] | Median [IQR] | Group differences | |
| Acetate | 67.3 [63.9–69.6] | 65.2 [59.7–70.4] | 66.6 [61–70.4] | n.s. |
| Butyrate | 11.0 [7.7–12.9] | 13.9 [10.4–19.5] | 12.7 [9.7–17.7] | ANT1-ANT2**, ANT1-NW* |
| Propionate | 12.9 [11.6–15.7] | 13.9 [11.6–16.1] | 14.9 [12.7–17.4] | n.s. |
| Valerate | 3.0 [2.1–4.7] | 2.5 [1.8–4.0] | 1.6 [1.1–2.4] | ANT1-NW***, ANT2-NW** |
| Total BCFA | 4.7 [3.3–6.3] | 4.0 [2.9–4.9] | 3.0 [2.3–3.8] | ANT1-NW***, ANT2-NW** |
SCFA concentrations (A) and the relative proportion of specific SCFA in relation to total SCFA (B) are presented. The p-values were false discovery rate (FDR) adjusted. A FDR < 0.05 was considered as statistically significant. *Indicates a FDR < 0.05 and **a FDR < 0.01. BCFA, branched chain fatty acids.